Navigation Links
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
Date:4/10/2012

BEDMINSTER, N.J. and SYDNEY, April 10, 2012 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today successful completion of two Phase 1 studies in healthy volunteers for MoxDuo® CR, a controlled-release Dual-Opioid® utilising a 3:2 ratio of morphine and oxycodone. The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and tamper resistant features, is designed to provide at least 12 hours of analgesia in patients suffering from moderate to severe chronic pain including cancer, lower back, osteoarthritis and neuropathic pain. The clinical trials compared blood levels of MoxDuo CR's components to OxyContin® and MS Contin® and demonstrated MoxDuo CR's superior results, with sustained blood levels for up to 24 hours. Further studies indicated MoxDuo CR's increased resistance to tampering.

"The successful completion of these trials confirms the advantages of this formulation and enables QRxPharma to initiate Phase 2 Proof-of-Concept clinical studies mid-year 2012," said Dr. John Holaday, Managing Director and Chief Executive Officer of QRxPharma. "These data suggest MoxDuo CR may be positioned as a once or twice per day formulation for treating chronic pain, with the potential advantage of significantly reduced side effects as witnessed with immediate release MoxDuo. In the US alone, the chronic opioid pain market is a $6 billion a year opportunity."

Two Phase 1 trials were conducted in healthy volunteers to evaluate the rate at which key components of the MoxDuo controlled-release (CR) formulation were absorbed, distributed, metabolised and eliminated by the body. The first study compared MoxDuo CR (30mg morphine SO4/20mg oxycodone HCl) to the pharmacokinetic profiles of the same doses of MS Contin (30mg morphine SO4) and OxyContin (20 mg oxycodone HCl) in 10 healthy adult human subjects using a three-way crossover design. Pharmacokinetic results from the measu
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 For the first time, cardiac surgeons, ... of the SynCardia temporary Total Artificial Heart in a ... on the Journal of Visualized Experiments website. ... on the SynCardia Total Artificial Heart implantation   ... of the SynCardia Total Artificial Heart," a July 18, ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, ... developing better, faster and affordable treatments, announced the ... Vice President, External Affairs. Mr. Brock comes to ... of Major Donor Relations for WWF International (formerly ... role, Mr. Brock will guide the TB Alliance,s ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli 2014 ... Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für den ... Shamir , ein weltweit anerkannter Manager im ... Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär der ...
Breaking Medicine Technology:How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3
(Date:7/31/2014)... Star Comedy Night will take place on August 7th at ... Moskowitz who has Neuroblastoma, a form of childhood cancer. Two ... have multiple ties to Avery and her family. Together, they ... at securing sponsors. Avery's story is being documented daily though ... Toyota and NY Auto Giant has generously ...
(Date:7/31/2014)... 2014 The rising population of baby ... the global geriatric care services market wherein a new ... these services across the globe. There are service providers ... agency to few large companies with national and even ... and is also highly fragmented. The developed nations have ...
(Date:7/31/2014)... improve when their ADHD is treated with medication, ... At least 25 percent of clinic-referred children with ... , "Parents with ADHD are at increased risk ... disciplinary practices, making ineffectual commands and diminished use ... psychiatry. "Having a parent with ADHD also decreases ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... believed to be the largest genetic analysis of what ... common childhood blood cancer, researchers at NYU Langone Medical ... drug target for treating the disease. , T-cell ... and aggressive childhood blood cancers. An estimated quarter of ... cancer each year in the U.S. fail to achieve ...
Breaking Medicine News(10 mins):Health News:Local Long Island Massage Day Spa and Auto Dealer Combine Forces to Raise Funds for 4 Year Old Who Has Cancer 2Health News:Local Long Island Massage Day Spa and Auto Dealer Combine Forces to Raise Funds for 4 Year Old Who Has Cancer 3Health News:Geriatric Care Services Market (Home Care, Adult Day Care, and Institutional Care): Global Industry Analysis, Size, Share, Growth, Forecast 2013 - 2019 2Health News:Geriatric Care Services Market (Home Care, Adult Day Care, and Institutional Care): Global Industry Analysis, Size, Share, Growth, Forecast 2013 - 2019 3Health News:Geriatric Care Services Market (Home Care, Adult Day Care, and Institutional Care): Global Industry Analysis, Size, Share, Growth, Forecast 2013 - 2019 4Health News:Geriatric Care Services Market (Home Care, Adult Day Care, and Institutional Care): Global Industry Analysis, Size, Share, Growth, Forecast 2013 - 2019 5Health News:Parenting skills improve in ADHD parents with medication 2Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Drug target identified for common childhood blood cancer 2Health News:Drug target identified for common childhood blood cancer 3
... (USMHRP) researcher Victoria R. Polonis, Ph.D., and colleagues released ... HIV-1 strains from six major clades in the 5 ... neutralizing antibodies are likely to play a key role ... looked specifically at the role of clade in eliciting ...
... help change the,prevention and treatment paradigm for sudden ... a white paper during their 2008,Annual Convention and ... a national health priority and bringing it to ... Sudden Cardiac,Arrest: Advancing Awareness and Bridging Gaps to ...
... 7 Go Healthy Inc. (Pink,Sheets: GOHE) announced today ... one of the largest churches in the state of ... as saying, "Several of,the church,s most prominent members are ... products in their snack area before and after,services." The ...
... China, Aug. 7 /Xinhua-PRNewswire-FirstCall/ -- Aamaxan,Transport Group, ... Board: AAXT),through its subsidiaries, including Shanghai Medical ... and a leading provider of Hemodialysis,equipment ("HDE") ... and diagnostic products, throughout Eastern China, today,announced ...
... 7 ChemBridge Research Laboratories,Inc. (CRL) announced today ... time for hit-to-lead follow-up libraries. Such ultra-fast,hit-to-lead libraries ... in a,matter of three to six days which ... and sets a new industry benchmark.,This state-of-the-art high-throughput ...
... The Board of Directors,of Endocare, Inc. (Nasdaq: ENDO ... HealthTronics, Inc. (Nasdaq: HTRN ) to purchase all ... per share in cash., Endocare,s Board of Directors, ... financial and legal advisors, will review and,consider HealthTronics, unsolicited ...
Cached Medicine News:Health News:Study sees need for standardized evaluation of antibody response to HIV-1 2Health News:Making Sudden Cardiac Arrest a National Health Priority: National Medical Association Issues White Paper on Sudden Cardiac Arrest 2Health News:Go Healthy Receives letter of Recognition from Large Texas Based Church 2Health News:Shanghai Medical Technology Co., Appoints Chief Financial Officer 2Health News:Shanghai Medical Technology Co., Appoints Chief Financial Officer 3Health News:ChemBridge Research Laboratories, Inc. (CRL) has Established an Industry Record and Benchmark in Hit-to-Lead Libraries Turn-around Time 2Health News:Endocare Comments on Unsolicited Proposal 2
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Medicine Products: